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parametersAbstract Recently, non nutritive sweeteners that can substitute for sucrose (high in calorie) cause
increased the prevalence of overweight children and adults. Non-caloric or low caloric sweeteners as
tools for making healthful food choices have been introduced to satisfy consumer demand. The aim
of this study was to evaluate the effect of stevia sweetener as a substitute sucrose at different doses
(25, 250, 500 and 1000 mg/kg b. wt/day) for twelve weeks on the weight management and on several
hematological and biochemical parameters of female rats. The results showed significant improvement
and ameliorated reduction in final bodyweight, bodyweights gain (%) (BWG) and feed efficiency ratio
(FER) in the stevia sweetener groups compared with the control. Stevia sweetener at 500 mg/kg b.
wt/day helps in weight loss of rats, decrement in the total cholesterol, triglycerides and low-density
lipoprotein concentration, increment in the high-density lipoprotein and no significant differences in
mean serum alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase
(ALP), or acid phosphatase (ACP) levels as compared to the control rats, which may be considered
as therapeutic beneficial. Also, this dose may be considered as a safe dose for people with diabetes,
especially the many individuals who need to lose weight to help control their blood glucose levels.
 2016 Production and hosting by Elsevier B.V. on behalf of Faculty of Agriculture, Ain Shams
University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Overweight and obesity have been amajor health concern in the
worldwide and as a risk factor of heart disease, diabetes, several
types of cancer, hypertension, arthritis, and othermusculoskele-
tal problems (NCHS; 2003). The World Health Organization
estimated the adult prevalence of overweight (BMI 25–29.9) at
1.5 billion globally in 2008, of which obese adults (BMIP 30)
numbered 500 million; by 2015, these figures are projected to
156 N.I.E. Abo Elnaga et al.rise to 2.3 billion overweight and 700 million obese adults
(WHO, 2011). Although diet (van Dam et al., 2002), physical
activity (Grilo, 1994 andTanasescu et al., 2000), and genetic fac-
tors (Yamada et al., 2006 and Scott et al., 2008) contribute to
obesity in children and adults, dietary behaviors such as a diet-
ary intake pattern (Regev-Tobias et al., 2012), including sugar
consumption, have been proved to have a potential impact on
this rapid weight gain (Bray et al., 2004).
In addition, new health-related concerns associated with the
consumption of sugar substitutes especially low-calorie sweet-
eners may not stimulate appetite, thereby not increasing calorie
intake and not promoting weight gain. Increasing consumer
demands for healthy, natural food products has spurred the
food industry’s interests in non- or low-caloric sweeteners of
natural rather than synthetic origin for example, stevia-
derived sweeteners (Kim and Kinghorn, 2002). Stevia
sweeteners are a natural, functional sweetener and medical sup-
plementary material that have received increasing industry and
scientific attention in recent years. Stevia sweeteners (stevio-
sides) are diterpene glycosides obtained from the leaves ofStevia
rebaudiana Bertoni (family Asteraceae) commonly called as
‘sweet herb‘ and these glycosides are also known as ‘sweeteners
of the future’ (Brahmachari et al., 2011; Lemus-Mondaca et al.,
2012). Steviosides, a natural non-caloric sweetener are 100–300
times sweeter than sucrose and contain a complex mixture of
sweet diterpene glycosides, including stevioside, steviolbioside,
rebaudiosides (A, B, C, D, E) and dulcoside A but the major
sweet constituents are stevioside and rebaudioside A. Due to
the sweetening property, steviosides have been widely used as
a non-caloric sugar substitute in many kinds of foods, beverage,
medicine, wine making, cosmetics, household chemical industry
and other food industries (Massoud et al., 2005a,b; Wolwer-
Rieck et al., 2010; Stoyanova et al., 2011). It is used for the treat-
ment of various conditions such as cancer (Takasaki et al.,
2009), diabetes (Lailerd et al., 2004), obesity, cavities, hyperten-
sion (Dyrskog et al., 2005), fatigue, depression, and in cosmetic
and dental preparations. It possesses hypoglycemic, hypoten-
sive, vasodilating, taste improving, sweetening, antifungal,
antiviral, anti-inflammatory, antibacterial (Ghosh et al., 2008)
properties and increases urination function of the body. How-
ever no significant toxicity has been reported with either ste-
vioside or stevia extract. The Joint Food and Agriculture
Organization/World Organization Expert Committee on Food
Additives (JECFA) in 2008, established an ‘‘acceptable daily
intake (ADI) of steviol up to 4 mg/kg bodyweight (b. wt), which
is equivalent to 10 mg/kg b. wt stevioside.
Replacing sugar with low-calorie sweeteners is a common
strategy for facilitating weight control. By providing sweet
taste without calories, intense sweeteners help lower energy
density of beverages and some foods.
The aim of this study was to investigate the effects and eval-
uate the best clinical amount consumption of stevia sweeteners
as a substitute for sucrose on weight gain or the weight loss
and weight management of female rats using different doses
(25, 250, 500 and 1000 mg/kg b. wt/day).
Materials and methods
Chemicals
The pure stevia sweetener was purchased from AWA for food
additives Co. Alexandria, Egypt. Sucrose (S) was supplied byEL-Gomhouria Co. Alexandria, Egypt. Commercial kits were
purchased from Bio-Diagnostic Co. Cairo, Egypt, except Lac-
tate dehydrogenase (LDH) was purchased from Bio-systems
Co. Alexandria, Egypt. All other chemicals used in this exper-
iment were of analytical grade.
Experimental design
Sixty adult femaleWistar strain rats (average weight 203 ± 6 g)
were used in the present experiment. Animals were obtained
from faculty of Medicine, Alexandria University, Egypt. The
local committee approved the design of the experiments and
the protocol conforms to the guidelines of the National
Institutes of Health (NIH). Animals were caged in groups of 6
and given distilled water and a standard diet that meets their
requirements for growing ad libitum. The diet consisted of
44% soybean cake; 12% berseem clover hay, 13.5% fat, 9.8%
yellow maize, 13.2% starch, 5% minerals; 2% lime stone and
0.5%vitamins mixture. After twoweeks of acclimatization, ani-
mals were divided into six equal groups. The first group was
drank distilled water (Negative control), and positive control
was given a dose of sucrose dissolved in drinking water at
500 mg/kg/day. This dose of sucrose used in this experiment
was predicted to dose of stevia sweeteners equivalent concentra-
tion estimated by JECFA as control. On the other hand, groups
3, 4, 5 and 6 were given a different doses of stevia sweeteners
which were dissolved in drinking water at a dose level of
25 mg/kg/day according to JECFA (G1), 250 mg/kg/day (G2),
500 mg/kg/day (G3) and 1000 mg/kg/day (G4), respectively.
Measured parameters
Fluid, food intake, Body weight, Feed efficiency ratio and
relative weight of organs
Fluid intake was recorded daily, and the intake of the sub-
stance being tested (mg/kg/day) was calculated from the mean
amount of fluid consumed (ml/kg/day) and the concentration
of the tested substance in the solution. Solution concentrations
were adjusted weekly based on the average weight of the ani-
mals and their current fluid consumption. At the end of the
experimental period (12 weeks), body weights of animals were
recorded and calculated of body weights gain (%) and feed
efficiency ratio (FER) according to the method of Chapman
et al. (1959).
Animals were sacrificed by exposure to an atmosphere of
100% diethyl ether and killed by decapitation. The brain, liver,
kidney and lung, heart, pancreas and spleen were immediately
removed and weighed then the organs weight ratio was calcu-
lated. The relative weight of organs (%) was calculated as
g/100 g body weight.
Blood hematological parameters
Rats of each group were euthanized at the end of treatment
period. Trunk blood samples were collected from the sacrificed
animals and blood samples were collected from vein plexus in
dry clean tubes with heparin (anti-coagulant). The non-
coagulated blood was used to determine red blood cell
(RBC), white blood cell (WBC), hemoglobin (HGB), mean
cell volume (MCV), mean cell hemoglobin (MCH), mean cell
hemoglobin concentration (MCHC), mean platelet volume
(MPV) and platelet count (PLT).
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Plasma samples were obtained by centrifugation at 860g for
20 min and the clear serum obtained was stored at 80 C till
measurements; serum was assayed for total lipids (TL) by the
method of Zollner and Kirsch (1962) and for cholesterol, by
the method of Allain et al. (1974). Triglycerides were deter-
mined by the methods of Fossati and Prenape (1982). High
density lipoprotein (HDL), low density lipoprotein (LDL)
and very low density lipoprotein (VLDL) were determined
according to the methods of Lopes-Virella et al. (1977), and
Wieland and Seidel (1983), respectively. Calculation of
LDL/HDL ratio was done. Also, the concentrations of glucose
were determined with enzymatic GOD/POD kits from
Bio-Diagnostic Co according to (Trinder, 1969) whereas urea
and creatinine levels were determined by the methods of
Fawcett and Soctt (1960) and Larsen (1972), respectively.
Serum total bilirubin was measured using the method of
Young (2001). Protein estimation was carried out according
to the method of Gornal et al. (1949). Albumin concentration
in the plasma was determined by the method of Doumas et al.
(1971). The serum globulin fraction was calculated by sub-
tracting the value of the albumin fraction from the total serum
protein Doumas et al. (1971). Alanine transaminase (ALT; EC
2.6.1.2) and aspartate transaminase (AST; EC 2.6.1.1) activi-
ties in the serum were determined according to the protocol
by Reitman and Frankel (1957). Colorimetric determination
of alkaline phosphatase activity was measured according to
the method of Belfield and Goldberg (1971). Serum acid phos-
phatase (ACP; EC 3.1.3.2) activity was measured as following
the method of Kind and King (1954). The activity of plasma
lactate dehydrogenase (LDH; EC 1.1.1.27) was determined
by the method of Scientific Commitee (1989). Thiobarbituric
acid reactive substances (TBARS) were measured in plasma
according to the method of Tappel and Zalkin (1959).Tissue enzyme activities and thiobarbituric acid reactive
substances
Liver was immediately removed at the end of the experiment
weight and washed using chilled saline solution. Tissue were
minced and homogenized (10% w/v) in ice-cold sucrose buffer
(2.25 mol) in homogenizer is Wise Tis HG-15D. The homoge-
nate was centrifuged at 10 000g for 30 min at 4 C. The resul-
tant supernatant of the organ was used for AST, ALT, ALP,
ACP, LDH and TBARS determination according to previous
methods.
Histological examination
Livers were obtained from rats, and immediately fixed in 10%
formalin, and then treated with conventional grade of alcohol
and xylol, embedded in paraffin and sectioned at 4–6 m thick-
ness. The sections were stained with Hematoxylin and Eosin
(H&E) stain for studying the histopathological changes.
The statistical analysis
The statistical analysis was carried out by one-way analysis of
variance (ANOVA). P values <0.05 were considered
significant.Results and discussionFirst of all there were no deaths and no signs of adverse reactions
to the treatment
Effect of administration of stevia sweetener on and sucrose (S)
on the weight gain, food consumption and feed efficiency ratio
(FER) in rats
Administration of stevia sweetener decreased feed intake as
compared to control group. Stevia sweetener at doses of
25 mg/kg b. wt showed the largest amounts of feed intake
(13.85 g/day), followed by 250 mg/kg b. wt (12.86 g/day), then
500 mg/kg b. wt (8.51 g/day) and finally the lowest amounts of
feed intake were found to be 1000 mg/kg b. wt stevia sweetener
(7.86 g/day). The average body weight gain was slightly
increased in all experimental groups during the first two weeks.
During the second weeks of the study, this average was
reduced in groups given stevia sweetener compared to control
groups (Fig. 1). Results revealed that the body weight gain
BWG% of rats decreased by 40.29%, 41.38%, 44.98%
and 48.29% when rats were given stevia sweetener at doses
of 25, 250, 500 and 1000 mg/kg b. wt respectively after
12 weeks. The decrease in body weight of rats might be due
to the absence of quick glucose releasing source or decrease
the caloric intake by rats.
Sucrose treated group (positive control) significantly
(P< 0.05) increased body weight and feed intake by 4.72%
and 14.22% respectively compared to negative control group.
Oral administration of stevia sweetener at doses of 25, 250, 500
and 1000 mg/kg b. wt significantly (P< 0.05) decreased the
BWG % when compared to positive control group, by
68.17%, 69.26%, 72.86% and 76.17% respectively, as shown
in Table 1. Sucrose-sweetened food and beverages resulted in
a 1.6 kg gain in overweight individuals (Raben et al., 2002).
These results support previous studies in which significant
reductions in body weight gain during growth and maturation
were observed in male rats receiving stevioside (Gregersen
et al., 2004) or 25 000 ppm rebaudioside A (Curry and
Roberts, 2008) or 150 022 mg/kg/day (Awney et al., 2010).
This may be due to increased lypolysis or the absence of
quick glucose releasing source. Moreover, Chang et al.
(2005) found that body weight of rats receiving 5.0 mg/kg ste-
vioside was reduced significantly in comparison with the group
receiving the diet without stevioside. This was probably due to
the poor palatability of the food because of the high amount of
stevioside. However, the non-caloric sweetener group had a
decrease in body mass index compared to an increase in body
mass index in the sucrose group (Raben et al., 2002 and Wiebe
et al., 2011).
Feed efficiency ratio (FER) revealed that stevia sweetener
at dose 1000 mg/kg b. wt showed the lowest FER value
(6.14), whereas rats given 500 mg/kg b. wt showed – 5.21
FER, those given 250 mg/kg b. wt showed – 3.22 FER and
those given 25 mg/kg b. wt showed – 2.91 FER. These results
supported the previous finding that the decrease in BWG was
related to stevia sweetener which might cause in loss of appe-
tite of rats Feed intake and FER value were significantly
(P< 0.05) increased in positive control group compared to
negative control group by 14.22%. These results supported
the previous finding that the increase in BWG was related to
the daily feed intake occurred in the animals (Fig. 2).
Table 1 Means of initial body weight, final body weight and
body weight gain % in control female rats and rats treated with
different levels of stevia sweetener after 12 weeks.
Experimental groups Body weight (gm) Body weight
gain (%)
Initial body
weight
Final body
weight
Negative control 203a 254b 25.12a
Positive control 208a 266a 27.88a
Stevia sweetener (25 mg/
kg b. wt)
206a 123c 40.29b
Stevia sweetener
(250 mg/kg b. wt)
203a 119c 41.38bc
Stevia sweetener
(500 mg/kg b. wt)
209a 115c 44.98cd
Stevia sweetener
(1000 mg/kg b. wt)
205a 106d 48.29d
Significant difference between control and all other groups by one-
way ANOVA (P< 0.05).
The values with different superscripts within each column are sig-
nificantly different at P< 0.05.
Fig. 2 Final body weight, feed intake and body weight gain % in
rats treated with administration of stevia sweetener after 12 weeks.
Fig. 1 Body weight of rats treated with administration of
sucrose (S) and stevia sweetener compared with control.
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not increasing calorie intake and not promoting weight gain
(Robarts and Wright, 2010). This finding agreed with the pre-
vious work of Awney et al. (2010), Bernal et al. (2011) and Abd
El-Razek and Massoud (2012) which showed that there was a
positive correlation between the decrease of body weight gain
percent and the reduction in feed intake and the dose of ste-
vioside administrated to rats.
Effect of administration of stevia sweetener on absolute and
relative organs weight
Treated rats with stevia sweetener at doses of 25, 250 and
500 mg/kg b. wt/day for 12 weeks had insignificant decreased
in relative to liver, heart, kidney, lung, pancreas and spleen
weight and had insignificant increased in relative to brain
weight when compared with positive or negative control
groups. Moreover, administration of stevia sweetener at dose
1000 mg/kg b. wt/day showed significant decrease in kidney
relative weight compared to the other treatment (Fig. 3).
Nikiforov and Eapen (2008) demonstrated that in a 90-daytoxicological study of rebaudioside A, some relative (to body
weight) organ weights were statistically significantly different
from the control group, but with the exception of reduced
absolute liver weight in male rats treated with 2000 mg/kg/day
of rebaudioside A, and there were no differences in mean abso-
lute brain weight. Also, Awney et al. (2010) found that the liver
weight to body weight ratio was significantly lower in the high
dose of stevioside (1500 mg/kg/day) group than in the control
group, while significant increases in brain were observed in the
low dose of stevioside (15 mg/kg/day) group when compared
with the control group.
Effect of administration of stevia sweetener on blood
hematological parameters of rats
Results showed that there was no significant change in WBC,
RBC, HGB, MCH and PLT between all the groups of rats.
While stevia sweetener groups showed a significant decrease
in MCHC and MPV when compared to negative control group
(Table 2).
Serum biochemical parameters and liver enzymes activities in
female rats treated with stevia sweetener
Groups of rats treated with stevia sweetener showed improve-
ment in lipid profile levels comparing with negative or positive
control group (Table 3).
It can be seen that the level of TL was decreased by 11.96%,
19.89%, 25.03% and 37.07% when rats were given stevia
sweetener at doses of 25, 250, 500 and 1000 mg/kg/b. wt,
respectively compared to negative control. Nevertheless Serum
lipids of rats given stevia sweetener at dose 1000 mg/kg showed
the lowest total cholesterol (TC) (168.12 mg/dl) followed by
that given the dose 500 mg/kg (175.38 mg/dl), dose 250 mg/
kg (180.25 mg/dl) and then finally dose 25 mg/kg (185.88 mg/
dl). Administration of stevia sweetener in a dose of 25 mg/kg
b. wt to female rats for 12 weeks showed no significant change
in serum TG, HDL and VLDL when compared to the positive
and negative control groups. The LDL values in rat serum
lipids decreased with increasing the doses of stevia sweetener.
Rats given stevia sweetener at dose 1000 mg/kg b. wt showed
the highest decrease in the LDL (26.50%) followed by those
given dose 500 mg/kg (24.36%), dose 250 mg/kg (19.90%)
and finally dose 25 mg/kg (15.01%). In contrast to LDL, level
of high density lipoprotein (HDL) increased with increasing
the doses of stevia sweetener. Results revealed that treatment
with stevia sweetener decreased serum levels of VLDL as
Table 2 Means of WBC, HGB, RBC, HCT, MCV, MCH, MCHC, MPV and PLT in control female rats and rats treated with
different levels of stevia sweetener after 12 weeks.
Parameter Experimental groups
Negative
control
Positive
control
Stevia sweetener
(25 mg/kg b. wt)
Stevia sweetener
(250 mg/kg b. wt)
Stevia sweetener
(500 mg/kg b. wt)
Stevia sweetener
(1000 mg/kg b. wt)
WBC (103/UL) 10.1ab 8.94ab 9.13ab 9.26ab 10.52ab 8.79b
HGB (g/dl) 11.75a 12.96a 12.48a 12.43a 13.03a 12.65a
RBC (106/ml) 5.32a 5.96a 5.77a 5.79a 5.85a 5.82a
HCT (%) 31.47b 34.36a 33.40ab 33.6ab 34.56a 34.58a
MCV (fl) 58.3c 62.22a 60.3b 60.62b 61.5ab 61.78ab
MCH (P g) 21.9a 21.52a 21.85a 21.85a 21.60a 21.80a
MCHC (P g) 36.8a 35.02b 34.93b 35.13b 34.58b 35.4ab
PLT (103/UL) 587a 529.5a 578a 573.5a 531.2a 521.25a
MPV (fl) 6.66a 6.72a 6.28b 6.14b 6.22b 6.32b
WBC= white blood cells; RBC= red blood cells; HGB= hemoglobin; HCT= hematocrit; MCV= mean cell volume; MCH=mean
corpuscular hemoglobin; MCHC=mean corpuscular hemoglobin concentration; MPV=mean platelet volume and PLT = platelets count.
Significant difference between control and all other groups by one-way ANOVA (P< 0.05).
The values with different superscripts within each column are significantly different at P< 0.05.
Table 3 Means of serum lipid profile levels (mg/dl) in control female rats and rats treated with different levels of stevia sweetener after
12 weeks.
Parameter Experimental groups
Negative
control
Positive
control
Stevia sweetener (25 mg/
kg b. wt)
Stevia sweetener (250 mg/
kg b. wt)
Stevia sweetener (500 mg/
kg b. wt)
Stevia sweetener (1000 mg/
kg b. wt)
TL 448.5a 455.13a 394.88b 359.25bc 336.25c 282.25d
TC 203a 206.63a 185.88b 180.25bc 175.38cd 1.69d
T.G 101.13a 105.38a 102.38a 90b 81.88c 80.25c
HDL 37.88b 37.25b 41.13ab 45.13a 46a 47.25a
LDL 130a 140.13a 119.1b 112.25bc 106c 103.13c
LDL/HDL 3.43ab 3.76a 2.90bc 2.49bc 2.30c 2.18c
VLDL 20.13ab 21.25a 19.5ab 17.88bc 16.13cd 1.28d
TL: total Lipid, TC: Total Cholesterol, TG: Triglyceride, HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein and VLDL: Very
Low Density Lipoprotein, Significant difference between control and all other groups by one-way ANOVA (P< 0.05).
The values with different superscripts within each column are significantly different at P< 0.05.
Fig. 3 Organ weights relative to body weight of female rats treated with stevia sweetener at doses of 25, 250, 500 and 1000 mg/kg b. wt
and sucrose compared with control.
Biochemical’s parameters 159compared to the negative or positive control group. The
VLDL levels were decreased 3.13%, 11.18%, 19.87% and
26.08% in rats given stevia sweetener at doses of 25, 250,
500 and 1000 mg/kg b. wt respectively when compared to the
negative control group. The LDL/HDL ratio was further
reduced to the lowest value in groups given stevia sweetener
as compared to the negative and positive control groups.It could be suggested that the reduction of lipid profile may
be due to the reduction of blood glucose levels after treatment
with different doses of stevia sweetener because it possesses
insulinotropic, glucagonostatic, antihyperglycemic, and
blood-pressure-lowering effects (Gregersen et al., 2004 and
Hony et al., 2006). These results are conforming to the results
of Curry and Roberts (2008) and Rajesh et al. (2012) who
Table 4 Means of serum biochemical parameters and liver enzymes activities in female rats treated with stevia sweeteners.
Parameter Experimental groups
Negative
control
Positive control Stevia sweetener
(25 mg/kg b. wt)
Stevia sweetener
(250 mg/kg b. wt)
Stevia sweetener
(500 mg/kg b. wt)
Stevia sweetener
(1000 mg/kg b. wt)
Glucose (mg/
dl)
101.34 ± 1.61b 113.59 ± 1.84a 90.65 ± 2.92c 86.85 ± 2.61cd 85.29 ± 2.9cd 83.30 ± 2.91d
Urea (mg/dl) 35.47 ± 0.98a 36.61 ± 0.97a 35.37 ± 0.15a 35.33 ± 0.15a 35.15 ± 0.19a 35.13 ± 0.05a
Creatinine
(mg/dl)
1.18 ± 0.06a 1.19 ± 0.085a 1 ± 0.027b 0.90 ± 0.038b 0.90 ± 0.057b 0.95 ± 0.029b
Bilirubin
(mg/dl)
2.65 ± 0.089a 2.69 ± 0.07a 2.35 ± 0.087b 2.33 ± 0.117b 2.32 ± 0.129b 2.31 ± 0.086b
Total Protein
(mg/dl)
7.02 ± 0.189b 7.25 ± 0.016a 7.01 ± 0.017b 7.01 ± 0.026b 7.01 ± 0.016b 7 ± 0.013b
Albumin
(mg/dl)
3.51 ± 0.14a 3.60 ± 0.08a 3.46 ± 0.07a 3.45 ± 0.09a 3.46 ± 0.11a 3.40 ± 0.09a
Globulin
(mg/dl)
3.51 ± 0.238a 3.61 ± 0.081a 3.65 ± 0.071a 3.56 ± 0.096a 3.59 ± 0.091a 3.61 ± 0.091a
AST (U/L) 109.53 ± 2.07a 110.39 ± 2.25a 107.76 ± 3.25a 106.4 ± 4.14a 104.63 ± 2.47a 102.43 ± 3.95a
ALT (U/L) 82.54 ± 0.96a 82.66 ± 0.57a 81.51 ± 2.80ab 78.38 ± 3.09ab 77.09 ± 2.6ab 75.5 ± 2.31b
AIP (U/L) 73.66 ± 1.14a 74.92 ± 1.02a 73.54 ± 1.88a 70.48 ± 4.14a 70.59 ± 1.73a 70.3 ± 1.53a
ACP (U/L) 16.83 ± 0.67a 17.14 ± 0.14a 16.66 ± 0.54a 16.66 ± 0.54a 16.47 ± 0.72a 16.29 ± 0.31a
LDH (U/L) 202.38 ± 8.53ab 217.41 ± 5.60a 196.3 ± 7.76bc 194.28 ± 2.65bc 192.26 ± 4.77bc 184.02 ± 4.01c
TBARS (U/
L)
2.28 ± 0.195a 2.34 ± 0.049a 2.15 ± 0.033a 1.88 ± 0.012b 1.85 ± 0.051b 1.77 ± 0.05b
AST: aspartate transaminase, ALT: alanine transaminase, ALP: alkaline phosphatase, ACP: acid phosphatase, LDH: Lactate dehydrogenase
and TBARS: thiobarbituric acid reactive substances. Significant difference between control and all other groups by one-way ANOVA
(P< 0.05).
The values with different superscripts within each column are significantly different at P< 0.05.
160 N.I.E. Abo Elnaga et al.revealed that stevioside significantly lowers in total cholesterol,
triglyceride, LDL-C and VLDL and improved HDL-C level as
compared with untreated rats. However, Park and Cha (2010)
found that total cholesterol concentrations were lower in rats
fed stevioside 1 ml kg per day with high fat diet compared to
rats fed high fat diet with water.
The plasma glucose concentrations were significantly
reduced after 12 weeks of the treatment by 25, 250, 500 and
1000 mg stevia sweetener/kg b. wt by 20.2%, 23.54%,
24.91% and 26.67% respectively as compared to the glucose
value of rats given sucrose (Table 4). Previous study showed
that stevioside was able to regulate blood glucose levels by
enhancing not only insulin secretion and sensitivity but also
insulin utilization in insulin deficient rats which was due to
decreased PEPCK gene expression in rat liver, and in addition,
no effect on blood glucose in healthy human subjects was
observed after treatment with 250 mg stevioside 3 times daily
for 1 year (Geuns et al., 2007). These results are in agreement
with Youssef et al. (2007), who found that administration of
stevia leaves or stevioside decreased glucose in serum diabetic
rats. Also, Awney et al. (2010) reported that administration of
stevioside at dose 1500 mg/kg/day caused significant reduction
(41%) on glucose level of rats, whereas no significant effects
were detected in low dose of stevioside (15 mg/kg). In the same
respect Table 4 shows, that the rats treated with sucrose (pos-
itive control group) had significant (P< 0.05) increase in glu-
cose level compared to normal rats (negative control group).
The present results revealed that stevia sweetener decreased
creatinine and bilirubin levels as compared to control, while
there was no significant change in serum urea in female rats
as compared to control (Table 4). This reduction was associ-
ated with decrease in kidney relative weight when comparedwith control groups. Contrary to our result, in previous study
by Toskulkao et al., 1995a,b when stevioside is given subcuta-
neously to rats (1.5 g/kg BW) and via intragastric tube to ham-
sters (4.1 g/kg BW), it caused nephrotoxicity as indicated by an
increase in blood urea nitrogen and plasma creatinine levels.
Curry and Roberts (2008) found that there was a tendency
in both males and females for the plasma urea and creatinine
results to be higher and the urine volume to be lower, espe-
cially in the higher dose of rebaudioside A orally treated rats.
They suggested that increases in urea and creatinine were due
to physiological rather than a toxicological effect as the
increases in mean urea and creatinine were relatively small
(1.1-and 1.2-fold, respectively), mean values all remained
within the laboratory’s reference ranges and no histological
evidence of kidney toxicity was observed. This result is in
accordance with the findings that no significant change in urea
in plasma of rats were observed when given stevia sweetener at
25 mg/kg/day as compared to control (Abd El-Razek and
Massoud, 2012).
Groups of rats treated with stevia sweetener had no signif-
icant increase in the level of globulin and significantly
(P< 0.05) decreased the serum levels of albumin (ALB) and
total protein (TP) compared to the negative control group.
AST and ALT are considered as a specific indicator for hepatic
dysfunction and damage (Osuna et al., 1977; Shakoori et al.,
1994). These enzymes are involved in the breakdown of amino
acids into a Keto acid which are routed for complete metabo-
lism through the Kreb’s cycle and electron transport chain.
Acid (ACP) and alkaline (ALP) phosphatase enzymes have
very similar catalytic functions and structures, but act within
different ranges of pH, and ALP is a widely used marker for
both skeletal and hepatobiliary disorders.
Fig. 4 Light microscopic photograph of rat liver tissues drinking on (a) distilled water; negative control, (b) sucrose dissolved in drinking
water, (c, d, e, and f) stevia sweeteners dissolved in water at a doses of 25, 250, 500 and 1000 mg/kg b. wt, respectively after 12 weeks.
Table 5 Means of TBARS and the activities of AST, AST, ALP, ACP and LDH in liver of female rats treated with stevia sweetener at
different doses after 12 weeks.
Parameter Experimental groups
Negative
control
Positive
control
Stevia sweetener (25 mg/
kg b. wt)
Stevia sweetener (250 mg/
kg b. wt)
Stevia sweetener (500 mg/
kg b. wt)
Stevia sweetener (1000 mg/
kg b. wt)
AST 141.67a 143.33a 141.29ab 140b 136.67c 135c
ALT 115.33ab 116.71a 114.07ab 113.43ab 112.8b 112.80b
ALP 72.25a 73.39a 71.78ab 71.74b 71.66b 71.07b
ACP 17.97a 18.09a 17.84a 17.74a 17.68a 17.39a
LDH 137.62b 145.71a 132.22bc 129.52cd 124.12de 121.43e
TBARS 63.63a 65.39a 62.85a 57.49b 51.7c 48.63c
AST: aspartate transaminase, ALT: alanine transaminase, ALP: alkaline phosphatase, ACP: acid phosphatase, LDH: Lactate dehydrogenase
and TBARS: thiobarbituric acid reactive substances.
Significant difference between control and all other groups by one-way ANOVA (P< 0.05).
The values with different superscripts within each column are significantly different at P< 0.05.
Biochemical’s parameters 161Our data indicated that treatment with stevia sweetener at
four dosage levels showed remarkably amelioration of the ele-
vation of enzymes level and the reduction in AST, ALP and
ACP enzymes activity compared with untreated group indicat-
ing that stevia sweetener tended to prevent damage and sup-
pressed the leakage of enzymes through cellular membranes.
Treatment with 1000 mg stevia sweetener/kg b. wt/day to rats
caused significant decrease in the levels of ALT and LDH
enzymes by 8.53% and 9.07% respectively, when compared
to the negative control group at the end of 12 week.
Our study showed that treatment of rats with stevia sweet-
ener at doses of 250, 500 and 1000 mg/kg b. wt/day signifi-
cantly decreased serum thiobarbituric acid reactive
substances (TBARS) by 17.54%, 18.86% and 22.37% respec-
tively, when compared to negative control group while stevia
sweetener at dose 25 mg/kg b. wt/day showed no significant
change in TBARS (Table 4).
This result was in agreement with Williams (1995) who
found that the diets given to rats containing stevia extract atlevels two 1% and 2% and stevioside at levels 1%, 2% and
3% led to gradual reduction in plasma AST and ALT levels.
Other study with Youssef et al. (2007) stated that diets con-
taining S. rebaudiana leaves at three levels 1%, 2% and 3%
and stevioside administrated at two levels 0.5% and 1%
decrease levels of AST and ALT. Agamy et al. (2008) found
that treating rats with different doses (100 or 200 mg ste-
vioside/kg b. wt/day) induced insignificant change in the
plasma liver function enzymes levels in reference to control
level. Parrimalavalli and Radhai (2010) suggested that rats
treated with S. rebaudiana extract at doses of 500, 1000 and
2000 mg/kg b. wt/day caused decrease in AST, ALT and
ALP values.Effect of stevia sweetener on TBARS and the activities of AST,
AST, ALP, ACP and LDH changes in liver of female rats
Results indicated that TBARS level was significantly
(P< 0.05) decreased in liver of rats treated with stevia
162 N.I.E. Abo Elnaga et al.sweetener at doses of 250, 500 and 1000 mg/kg/day (Table 5).
Treatment with stevia sweetener at doses of 500 and 1000 mg
caused significant (P< 0.05) decrease in the activities of
AST and ALT enzymes compared to both negative and posi-
tive controls. In addition, treatment with stevia sweetener in
low dose (25 mg/kg b. wt/day) reduced ALP and TBARS
levels compared to positive control group. Results revealed
that LDH value in liver of rats decreased by 9.26%, 11.11%,
14.82% and 16.66% when rats were given stevia sweetener at
doses of 25, 250, 500 and 1000 mg/kg b. wt, respectively after
12 weeks.
Histological examination of liver tissues
Histopathological examination of the liver taken from control
group (Fig. 4a) and stevia sweetener treated groups (Fig. 2c–f)
showed normal appearance with regular arrangement of hepa-
tocyte cell, no fibrosis, mild inflammation and normal hepatic
cells with well preserved cytoplasm, nucleus and nucleolus and
central vein.
In conclusion, stevia sweetener treated groups showed sig-
nificantly improvement and ameliorated reduction in body-
weight, BWG % and lesser intake of feed. In addition stevia
sweetener proved to be beneficial in decreasing the levels of
blood glucose, total lipids, total cholesterol, triglycerides and
low-density lipoprotein concentrations, and increasing the
high-density lipoprotein.
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